我武生物 reported revenue of ¥0.51B for the period ended 2026-06-30, +6.2% year on year. Net income was ¥0.21B, a 40.6% net margin on a 95.3% gross margin. The largest revenue line is 粉尘螨滴剂 at 91% of the total. Free cash flow for the period was ¥0.13B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.51B | +6.2% |
| Gross profit | ¥0.49B | — |
| Operating income | ¥0.24B | — |
| Net income | ¥0.21B | +22.4% |
| Gross margin | 95.3% | Net margin 40.6% |
| Revenue Q/Q | +3.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 粉尘螨滴剂 | ¥0.47B | 91.4% |
| 黄花蒿花粉变应原舌下滴剂 | ¥0.04B | 6.9% |
| 皮肤点刺液 | ¥0.01B | 1.1% |
| 其他 | ¥0.00B | 0.1% |
| 研发服务 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.02B | 4.7% |
| R&D | ¥0.05B | 9.3% |
| SG&A | ¥0.24B | 45.8% |
| Tax & other | ¥0.04B | 6.9% |
| Item | Amount |
|---|---|
| Total assets | ¥3.08B |
| Total liabilities | ¥0.24B |
| Shareholders' equity | ¥2.84B |
| Equity / assets | 92.3% |
| Operating cash flow | ¥0.13B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.13B |
| Cash conversion (OCF / net income) | 91% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
楚天科技 ・ 全通教育 ・ 炬华科技 ・ 博腾股份 ・ 中文在线 ・ 恒华科技 ・ ST创意 ・ 汇金股份 ・ 绿盟科技 ・ 安控科技 ・ 汇中股份 ・ 扬杰科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies